Aneal joined Sofinnova BioEquities as a senior analyst in 2019. He focuses on public investments primarily in commercial-stage, global healthcare companies. Aneal has nine years of healthcare experience with seven years in public investing roles.
Prior to Sofinnova, Aneal was a Senior Analyst at Citadel for five years where he helped manage a healthcare-focused portfolio. Before Citadel, Aneal was an Analyst at Point72 covering healthcare investments. Before public investing, Aneal was an Investment Banker at Greenhill where he focused on healthcare M&A.
Aneal received his B.B.A. from University of Texas-Austin where he graduated with high honors.